Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Feb 9;11:25. doi: 10.1186/s40478-023-01514-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 2 — ACVR1 expression is prognostic in PFAs and associated with transcriptomic signatures observed in ACVR1-mutant DMGs. a Frequency of 1q gain (Y-axis) in ACVR1-mutant (n = 31) vs. WT (n = 137) H3K27M DMGs from Mackay et al. [36]. b ACVR1 RNA expression levels (Y-axis) in PFAs (n = 19) compared to PFBs (n = 8) from Bayliss et al. 2016 [31]. Data analyzed by unpaired, two-tailed t test. c Progression-free survival (months) analysis comparing PFAs with ACVR1 high (the top quartile, n = 19) vs. low (lower three quartiles, n = 57) expression. d Overall survival (months) analysis comparing PFAs with ACVR1 high (the top quartile, n = 19) vs. low (lower three quartiles, n = 57) expression. Data in 2c-d analyzed using Kaplan–Meier, Log-Rank test with 95% confidence intervals. e Comparison of enriched pathways from differentially expressed genes in ACVR1-mutant vs. -wildtype H3K27M DMGs (from 2a, Y-axis) and ACVR1-high vs. -low PFAs (from 2d, X-axis). f Gene set enrichment analyses of the Hallmark epithelial-to-mesenchymal transition (EMT) pathway for genes ranked by differential expression in ACVR1-mutant DMGs or in high ACVR1 expressing PFAs. g Gene set enrichment analyses of the Hallmark hypoxia pathway for genes ranked by differential expression in ACVR1-mutant DMGs or in high ACVR1 expressing PFAs